Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

About this update from Relmada Therapeutics, Inc.

CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress. Conference Call and Webcast Information: A replay of the webcast will be available in the Investors section of the Relmada website at  https://www.relmada.com/investors/ir-calendar . About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs. For more information, visit  www.relmada.com Investor Contact: Brian Ritchie LifeSci Advisors [email protected] Media Inquiries: Corporate Communications [email protected]

View stock analysis, news, and events for Relmada Therapeutics, Inc.